Catabasis’s Future In Doubt After DMD Phase III Failure
Executive Summary
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
You may also be interested in...
COVID-19 Accounts For Most Of 2020’s Pharma Pipeline Growth
The impact of the coronavirus pandemic on the size of the pharma R&D pipeline in 2020 could be felt in a number of ways.
Shock As AstraZeneca’s Oncology R&D Head José Baselga Dies
AstraZeneca’s CEO Pascal Soriot confirmed the death of distinguished cancer researcher and head of its oncology R&D unit, José Baselga, on 21 March.
GSK’s Dostarlimab Gets EU Nod For Endometrial Cancer
While its NDA languishes at the US Food and Drug Administration, the EMA’s CHMP has said yes to dostarlimab’s marketing in the EU for endometrial cancer.